<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747523</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054784</org_study_id>
    <nct_id>NCT03747523</nct_id>
  </id_info>
  <brief_title>Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels</brief_title>
  <official_title>Study of the Effect of Ergocalciferol on Plasma and Urinary Mucin-1 Levels in Healthy Individuals and Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a one-time oral administration of ergocalciferol results in a decline in
      plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, open-labelled, to determine if oral administration of a single dose of
      ergocalciferol lowers plasma mucin-1 levels. The study population will include 40 healthy
      individuals and 40 individuals with ADTKD-MUC1.

      The study consists of an initial screening, signing of consent of interested individuals,
      performance of pregnancy test in women of child-bearing age and screening labs, and
      administration of 200,000 units of ergocalciferol on Day 0 (On Study). Laboratory studies
      will be performed at baseline, on Days 3, 7, and 10.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma mucin-1 levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma mucin-1 levels will be measured in both groups. using a two-tailed T-test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma mucin-1 levels</measure>
    <time_frame>4 days</time_frame>
    <description>Plasma mucin-1 levels will be measured in both groups. using a two-tailed T-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma mucin-1 levels</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma mucin-1 levels will be measured in will be measured in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma mucin-1 levels</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma mucin-1 levels will be measured in will be measured in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary mucin-1 levels in healthy controls</measure>
    <time_frame>Baseline</time_frame>
    <description>Urinary mucin-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary mucin-1 levels in healthy controls</measure>
    <time_frame>3 days</time_frame>
    <description>Urinary mucin-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary mucin-1 levels in healthy controls</measure>
    <time_frame>7 days</time_frame>
    <description>Urinary mucin-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary mucin-1 levels in healthy controls</measure>
    <time_frame>10 days</time_frame>
    <description>Urinary mucin-1 levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ergocalciferol</condition>
  <arm_group>
    <arm_group_label>Healthy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADTKD-MUC1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D</description>
    <arm_group_label>ADTKD-MUC1 Group</arm_group_label>
    <arm_group_label>Healthy Group</arm_group_label>
    <other_name>Drisdol</other_name>
    <other_name>Calciferol</other_name>
    <other_name>Calcidol</other_name>
    <other_name>Vitamin D2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and &lt;65 years

          -  Females must be non-pregnant, non-lactating and fulfilling one of the following: a.
             Post menopausal defined as amenorrhea for at least 12 months following cessation of
             all exogenous hormonal treatments. b. Status post irreversible surgical sterilization
             by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal
             ligation. c.

        Use of acceptable contraceptive method: IUD with spermicide, a female condom with
        spermicide, contraceptive sponge with spermicide, an intravaginal system(e.g., NuvaRing®),
        a diaphragm with spermicide, a cervical cap with spermicide, or oral, implantable,
        transdermal, or injectable contraceptives, sexual abstinence, or a sterile sexual partner.

          -  Males must agree to avoid fathering a child (or donating sperm), and therefore be
             either sterile or agree to use, from the time of enrollment until 45 days after end of
             study, one of the following approved methods of contraception: a male condom with
             spermicide, a sterile sexual partner, use by female sexual partner of an IUD with
             spermicide, a female condom with spermicide, contraceptive sponge with spermicide, an
             intravaginal system (e.g.,NuvaRing®), a diaphragm with spermicide, a cervical cap with
             spermicide, or oral, implantable, transdermal, or injectable contraceptives.

          -  No serious health conditions except for estimated glomerular filtration rate &lt;30
             ml/min/1.73 m2 (according to the modified MDRD formula) in participants with ADTKD-
             MUC1.

          -  Prior established genetic diagnosis of ADTKD-MUC1 in participants recruited with
             ADTKD-MUC1.

          -  Able to understand and comply with requirements of the entire study and to communicate
             with the study team.

          -  Living in close enough proximity to a local laboratory to obtain labwork for the
             study.

          -  Written informed consent using a document that has been approved by the Institutional
             Review Board.

          -  The participant has not taken ergocalciferol in the month prior to study initiation.
             If receiving cholecalciferol, the dose is &lt; 1000/day and has been stopped one month
             prior to Day 0 (On Study).

          -  Participants agree NOT to take ergocalciferol or cholecalciferol (except for&lt;500 IU
             that contained in a daily multi-vitamin) for six months after receiving the one-time
             dose of ergocalciferol.

        Exclusion Criteria:

          -  Major systemic illness other than chronic kidney disease in individuals with ADTKD-
             MUC1.

          -  A history of granulomatous disorders (sarcoidosis, tuberculosis), hyperparathyroidism,
             or other disorders of calcium metabolism.

          -  A history of nephrolithiasis.

          -  A history of osteoporosis or osteopenia.

          -  A fracture or a fall that did not occur during exercise within the last six months.

          -  Intolerance or known allergic reaction to ergocalciferol.

          -  25 hydroxy Vitamin D level &gt; upper limit of normal.

          -  Lactating.

          -  Liver disease.

          -  Receiving glucocorticoids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J. Bleyer, MD, M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirby A, Gnirke A, Jaffe DB, Barešová V, Pochet N, Blumenstiel B, Ye C, Aird D, Stevens C, Robinson JT, Cabili MN, Gat-Viks I, Kelliher E, Daza R, DeFelice M, Hůlková H, Sovová J, Vylet'al P, Antignac C, Guttman M, Handsaker RE, Perrin D, Steelman S, Sigurdsson S, Scheinman SJ, Sougnez C, Cibulskis K, Parkin M, Green T, Rossin E, Zody MC, Xavier RJ, Pollak MR, Alper SL, Lindblad-Toh K, Gabriel S, Hart PS, Regev A, Nusbaum C, Kmoch S, Bleyer AJ, Lander ES, Daly MJ. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet. 2013 Mar;45(3):299-303. doi: 10.1038/ng.2543. Epub 2013 Feb 10.</citation>
    <PMID>23396133</PMID>
  </reference>
  <reference>
    <citation>Bleyer AJ, Kmoch S: Autosomal Dominant Tubulointerstitial Kidney Disease, MUC1-Related. 1993</citation>
  </reference>
  <reference>
    <citation>Bleyer AJ, Kmoch S, Antignac C, Robins V, Kidd K, Kelsoe JR, Hladik G, Klemmer P, Knohl SJ, Scheinman SJ, Vo N, Santi A, Harris A, Canaday O, Weller N, Hulick PJ, Vogel K, Rahbari-Oskoui FF, Tuazon J, Deltas C, Somers D, Megarbane A, Kimmel PL, Sperati CJ, Orr-Urtreger A, Ben-Shachar S, Waugh DA, McGinn S, Bleyer AJ Jr, Hodanová K, Vylet'al P, Živná M, Hart TC, Hart PS. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar;9(3):527-35. doi: 10.2215/CJN.06380613. Epub 2014 Feb 7.</citation>
    <PMID>24509297</PMID>
  </reference>
  <reference>
    <citation>Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. 2015 Dec;72(23):4475-500. doi: 10.1007/s00018-015-2014-z. Epub 2015 Aug 21. Review.</citation>
    <PMID>26294353</PMID>
  </reference>
  <reference>
    <citation>Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, Yokoyama A, Kohno N, Bonella F, Guzman J, Ohshimo S, Costabel U. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir Med. 2012 Dec;106(12):1756-64. doi: 10.1016/j.rmed.2012.09.001. Epub 2012 Sep 18.</citation>
    <PMID>22995277</PMID>
  </reference>
  <reference>
    <citation>Janssen R, Kruit A, Grutters JC, Ruven HJ, Gerritsen WB, van den Bosch JM. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol. 2006 Apr;34(4):496-9. Epub 2005 Dec 15.</citation>
    <PMID>16357367</PMID>
  </reference>
  <reference>
    <citation>Ligtenberg MJ, Gennissen AM, Vos HL, Hilkens J. A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res. 1991 Jan 25;19(2):297-301.</citation>
    <PMID>2014168</PMID>
  </reference>
  <reference>
    <citation>Živná M, Kidd K, Přistoupilová A, Barešová V, DeFelice M, Blumenstiel B, Harden M, Conlon P, Lavin P, Connaughton DM, Hartmannová H, Hodaňová K, Stránecký V, Vrbacká A, Vyleťal P, Živný J, Votruba M, Sovová J, Hůlková H, Robins V, Perry R, Wenzel A, Beck BB, Seeman T, Viklický O, Rajnochová-Bloudíčková S, Papagregoriou G, Deltas CC, Alper SL, Greka A, Bleyer AJ, Kmoch S. Noninvasive Immunohistochemical Diagnosis and Novel MUC1 Mutations Causing Autosomal Dominant Tubulointerstitial Kidney Disease. J Am Soc Nephrol. 2018 Sep;29(9):2418-2431. doi: 10.1681/ASN.2018020180. Epub 2018 Jul 2. Erratum in: J Am Soc Nephrol. 2020 Apr;31(4):892.</citation>
    <PMID>29967284</PMID>
  </reference>
  <reference>
    <citation>Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem. 1995 Dec 15;270(50):30093-101.</citation>
    <PMID>8530414</PMID>
  </reference>
  <reference>
    <citation>Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, Johnston SE, Vrcic A, Wong B, Khan M, Asiedu J, Narayan R, Mader CC, Subramanian A, Golub TR. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med. 2017 Apr 7;23(4):405-408. doi: 10.1038/nm.4306.</citation>
    <PMID>28388612</PMID>
  </reference>
  <reference>
    <citation>Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2.</citation>
    <PMID>27108412</PMID>
  </reference>
  <reference>
    <citation>Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018 Jun 13;8(1):9039. doi: 10.1038/s41598-018-27297-1.</citation>
    <PMID>29899554</PMID>
  </reference>
  <reference>
    <citation>Conley SJ, Bosco EE, Tice DA, Hollingsworth RE, Herbst R, Xiao Z. HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. Oncogene. 2016 Aug 11;35(32):4225-34. doi: 10.1038/onc.2015.487. Epub 2016 Jan 4.</citation>
    <PMID>26725324</PMID>
  </reference>
  <reference>
    <citation>Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart M, Rothé F, Sotiriou C. Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. NPJ Breast Cancer. 2018 Aug 6;4:23. doi: 10.1038/s41523-018-0077-3. eCollection 2018.</citation>
    <PMID>30109263</PMID>
  </reference>
  <reference>
    <citation>Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013 Sep;24(9):2316-24. doi: 10.1093/annonc/mdt162. Epub 2013 May 9.</citation>
    <PMID>23661292</PMID>
  </reference>
  <reference>
    <citation>Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008 Jun;87(6):1738-42.</citation>
    <PMID>18541563</PMID>
  </reference>
  <reference>
    <citation>Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010 May 12;303(18):1815-22. doi: 10.1001/jama.2010.594. Erratum in: JAMA. 2010 Jun 16;303(23):2357.</citation>
    <PMID>20460620</PMID>
  </reference>
  <reference>
    <citation>Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf). 2009 May;70(5):685-90. doi: 10.1111/j.1365-2265.2008.03403.x. Epub 2008 Sep 2.</citation>
    <PMID>18771564</PMID>
  </reference>
  <reference>
    <citation>Kearns MD, Alvarez JA, Tangpricha V. Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review. Endocr Pract. 2014 Apr;20(4):341-51. doi: 10.4158/EP13265.RA. Review.</citation>
    <PMID>24246341</PMID>
  </reference>
  <reference>
    <citation>Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, Carnevale V, Scillitani A, Minisola S. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008 Aug;93(8):3015-20. doi: 10.1210/jc.2008-0350. Epub 2008 May 20.</citation>
    <PMID>18492750</PMID>
  </reference>
  <reference>
    <citation>Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006 Oct;84(4):694-7.</citation>
    <PMID>17023693</PMID>
  </reference>
  <reference>
    <citation>Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months. Br J Nutr. 2013 Mar 28;109(6):1082-8. doi: 10.1017/S0007114512002851. Epub 2012 Jul 11.</citation>
    <PMID>23168298</PMID>
  </reference>
  <reference>
    <citation>Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004 Nov;89(11):5387-91.</citation>
    <PMID>15531486</PMID>
  </reference>
  <reference>
    <citation>Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998 Oct;68(4):854-8.</citation>
    <PMID>9771862</PMID>
  </reference>
  <reference>
    <citation>Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012 Apr 1;4(2):191-7. doi: 10.4161/derm.20332.</citation>
    <PMID>22928076</PMID>
  </reference>
  <reference>
    <citation>Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2010 Oct;53(10):2112-9. doi: 10.1007/s00125-010-1838-1. Epub 2010 Jul 2.</citation>
    <PMID>20596692</PMID>
  </reference>
  <reference>
    <citation>Premaor MO, Scalco R, da Silva MJ, Froehlich PE, Furlanetto TW. The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. J Bone Miner Metab. 2008;26(6):603-8. doi: 10.1007/s00774-008-0858-0. Epub 2008 Nov 1.</citation>
    <PMID>18979160</PMID>
  </reference>
  <reference>
    <citation>Sakalli H, Arslan D, Yucel AE. The effect of oral and parenteral vitamin D supplementation in the elderly: a prospective, double-blinded, randomized, placebo-controlled study. Rheumatol Int. 2012 Aug;32(8):2279-83. doi: 10.1007/s00296-011-1943-6. Epub 2011 May 10.</citation>
    <PMID>21556746</PMID>
  </reference>
  <reference>
    <citation>Stoll D, Dudler J, Lamy O, Hans D, Krieg MA, Aubry-Rozier B. Can one or two high doses of oral vitamin D3 correct insufficiency in a non-supplemented rheumatologic population? Osteoporos Int. 2013 Feb;24(2):495-500. doi: 10.1007/s00198-012-1962-5. Epub 2012 Mar 17.</citation>
    <PMID>22426953</PMID>
  </reference>
  <reference>
    <citation>Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int. 2009 Aug;20(8):1407-15. doi: 10.1007/s00198-008-0814-9. Epub 2008 Dec 20.</citation>
    <PMID>19101755</PMID>
  </reference>
  <reference>
    <citation>Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007 Dec;46(12):1852-7. Epub 2007 Nov 12.</citation>
    <PMID>17998225</PMID>
  </reference>
  <reference>
    <citation>Amrein K, Sourij H, Wagner G, Holl A, Pieber TR, Smolle KH, Stojakovic T, Schnedl C, Dobnig H. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. Crit Care. 2011;15(2):R104. doi: 10.1186/cc10120. Epub 2011 Mar 28.</citation>
    <PMID>21443793</PMID>
  </reference>
  <reference>
    <citation>Rossini M, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, Adami S. Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃. J Clin Endocrinol Metab. 2012 Apr;97(4):E622-6. doi: 10.1210/jc.2011-2448. Epub 2012 Feb 1.</citation>
    <PMID>22298802</PMID>
  </reference>
  <reference>
    <citation>Tellioglu A, Basaran S, Guzel R, Seydaoglu G. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. Maturitas. 2012 Aug;72(4):332-8. doi: 10.1016/j.maturitas.2012.04.011. Epub 2012 May 20.</citation>
    <PMID>22613271</PMID>
  </reference>
  <reference>
    <citation>Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID; Fitness Collaborative Group. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc. 2003 Mar;51(3):291-9.</citation>
    <PMID>12588571</PMID>
  </reference>
  <reference>
    <citation>Leventis P, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2009 Mar-Apr;38(2):149-53. doi: 10.1080/03009740802419081.</citation>
    <PMID>18991184</PMID>
  </reference>
  <reference>
    <citation>Kearns MD, Binongo JN, Watson D, Alvarez JA, Lodin D, Ziegler TR, Tangpricha V. The effect of a single, large bolus of vitamin D in healthy adults over the winter and following year: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. 2015 Feb;69(2):193-7. doi: 10.1038/ejcn.2014.209. Epub 2014 Oct 1.</citation>
    <PMID>25271011</PMID>
  </reference>
  <reference>
    <citation>Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008 Aug;88(2):582S-586S. Review.</citation>
    <PMID>18689406</PMID>
  </reference>
  <reference>
    <citation>Lee JP, Tansey M, Jetton JG, Krasowski MD. Vitamin D Toxicity: A 16-Year Retrospective Study at an Academic Medical Center. Lab Med. 2018 Mar 21;49(2):123-129. doi: 10.1093/labmed/lmx077.</citation>
    <PMID>29346630</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.</citation>
    <PMID>10075613</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Drisdol</keyword>
  <keyword>Rickets</keyword>
  <keyword>Plasma</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>Autosomal Dominant Tubulo Interstitial Kidney Disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

